Summit Therapeutics Inc. SMMT

SMMT Company Overview

Summit Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for serious unmet medical needs, primarily in oncology and infectious diseases. The company’s core strategy centers on advancing differentiated drug candidates through late-stage clinical development, with a current emphasis on immune-oncology assets designed to improve outcomes beyond existing standards of care.

Summit’s primary value driver is its oncology pipeline, led by ivonescimab (also known as AK112), a novel bispecific antibody targeting PD‑1 and VEGF pathways. The company serves global oncology markets, with a strategic focus on the United States, China, and other major pharmaceutical markets. Summit’s positioning is defined by its selective asset acquisition strategy, capital discipline, and reliance on strategic partnerships to accelerate development while limiting internal infrastructure buildout. Founded in 2003, Summit initially focused on antibiotics before pivoting toward oncology through asset acquisitions and licensing agreements, most notably its collaboration with Akeso, Inc.